Julian Kött, Noah Zimmermann, Tim Zell, Isabel Heidrich, Glenn Geidel, Alessandra Rünger, Daniel J Smit, Myriam Merkle, Niousha Parnian, Inga Hansen, Inka Hoehne, Finn Abeck, Leopold Torster, Michael Weichenthal, Klaus Pantel, Stefan W Schneider, Christoffer Gebhardt
BACKGROUND: The treatment of melanoma has been revolutionized by the use of immune checkpoint inhibition (ICI), but many patients do not benefit. Furthermore, immune-related adverse events may occur during therapy. A predictive biomarker is needed to reliably identify patients benefitting. In lung, renal cell and bladder cancer early C-reactive protein (CRP) kinetics were shown to be a predictive biomarker for ICI. OBJECTIVE: Here, we investigate early CRP kinetics as predictive biomarker for ICI in melanoma patients...
March 11, 2024: Journal of the European Academy of Dermatology and Venereology: JEADV